41 completed, 9 terminated, 8 unknown, 4 recruiting. 32 Phase 2, 19 Phase 1, 13 Phase 3, 2 Not applicable, 2 Phase 4.
Follow Interferon-gamma: new trials by email Literature Review of Interferon-gamma trials Research Report on Interferon-gamma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo Interferon Gamma 1-b, Placebo - Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6 | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 170 | 2026-02-24 | 2026-11-12 |
| Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression Interferon Gamma 1-b, Placebo - Sustained Immunosuppression | Phase 3 | Recruiting | University Hospital, Limoges | 326 | 2025-07-09 | 2025-11-20 |
| Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients Interferon gamma, Placebo - Pneumonia, Ventilator-Associated | Phase 3 | Recruiting | Hospices Civils de Lyon | 132 | 2023-06-30 | 2026-07-06 |
| The 1st Tumor CytokinoTherapy Database (TCTD-1) Tumor necrosis factor alpha, Interferon gamma - Oncology | Recruiting | OncoCareClinic 308 Ltd | 5000 | 2022-09-19 | 2024-06-10 | |
| A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis Interferon-Gamma - Respiratory Tuberculosis | Unknown | SPP Pharmaclon Ltd. | 350 | 2022-06-01 | 2023-11-09 | |
| Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis Interferon-Gamma - Pulmonary Tuberculosis | Unknown | SPP Pharmaclon Ltd. | 84 | 2022-04-15 | 2022-06-01 | |
| Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone - Asthma | Phase 1 | Terminated | Emory University | 1 | 2022-03-16 | 2025-06-03 |
| Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Edwin Horwitz | 4 | 2021-12-02 | 2026-02-13 |
| Study of the Use of the Drug Ingaron in Patients With COVID-19 Interferon Gamma - COVID-19 Respiratory Infection, Viral Pneumonia | Completed | SPP Pharmaclon Ltd. | 36 | 2020-04-21 | 2022-05-27 | |
| Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab - Other Skin | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2019-07-03 | 2025-03-06 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab - Breast Cancer, Breast Cancer, Male | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 51 | 2017-06-23 | 2023-04-19 |
| Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia Interferon-Gamma - Community-acquired Pneumonia | Not applicable | Completed | SPP Pharmaclon Ltd. | 114 | 2017-05-12 | 2022-05-27 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| Effect of IFN-γ on Innate Immune Cells Administration of drug (Interferon-gamma 1-b) subcutaneously - Chronic Granulomatous Disease | Phase 1 | Completed | University of Colorado, Denver | 20 | 2016-07-01 | 2019-02-15 |
| Open Trail of γIFN for Friedreich Ataxia gamma interferon - Friedreich Ataxia | Phase 2 | Completed | IRCCS Eugenio Medea | 12 | 2016-06-26 | 2020-02-26 |
| Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors interferon-gamma and nivolumab - Advanced Solid Tumors | Phase 1 | Completed | Fox Chase Cancer Center | 26 | 2015-12-11 | 2019-11-29 |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors Single intratumoral injection of DNX-2401, Interferon-gamma - Glioblastoma or Gliosarcoma | Phase 1 | Completed | DNAtrix, Inc. | 37 | 2014-09-11 | 2018-07-16 |
| Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Laboratory Biomarker Analysis, Recombinant Interferon Gamma - Myxoid Liposarcoma, Round Cell Liposarcoma | Early Phase 1 | Terminated | Fred Hutchinson Cancer Center | 8 | 2013-09-25 | 2019-07-10 |
| Mother-caregivers of Children With Duchenne Muscular Dystrophy sleep parameters, Hormonal profile, Inflammatory profile - Other Diseases or Conditions | Not applicable | Completed | Monica Levy Andersen | 60 | 2013-08-01 | 2016-02-03 |
Showing 20 of 63. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (4) · Tuberculosis, Pulmonary (4) · Breast Neoplasms (3) · Granulomatous Disease, Chronic (3) · Melanoma (3) · Sepsis (3) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Friedreich Ataxia (2) · Graft vs Host Disease (2) · Hepatitis C (2) · Hepatitis C, Chronic (2) · Hodgkin Disease (2) · Immunologic Deficiency Syndromes (2) · Infections (2)
National Institute of Allergy and Infectious Diseases (NIAID) (7) · National Cancer Institute (NCI) (6) · SPP Pharmaclon Ltd. (5) · InterMune (4) · Fred Hutchinson Cancer Center (2) · Herbert Irving Comprehensive Cancer Center (2) · Radboud University Medical Center (2) · Accelerated Community Oncology Research Network (1) · Aga Khan University (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Policlinico Umberto I (1) · Charite University, Berlin, Germany (1) · Children's Oncology Group (1) · Columbia University (1) · DNAtrix, Inc. (1)
United States (40) · Russia (6) · France (4) · Australia (2) · Germany (2) · Italy (2) · Netherlands (2) · Brazil (1) · Canada (1) · Pakistan (1)
Anatoly I Saulin, Master (4) · Javier Szwarcberg, MD (2) · Allen R. Chen, MD, PhD, MHS (1) · Andrea Martinuzzi, MD (1) · Benjamin Chousterman, Professor (1) · Carlo Casali, MD (1) · Charles L. Wiseman, MD, FACP (1) · Charles S. Hesdorffer, MD (1) · Corine Delsing, MD (1) · Crystal L Mackall, M.D. (1) · Daniel R. Ambruso, MD (1) · David A Cooper, AO DSc MD FRACP FRCPA FRCP (1) · Edwin Horwitz, MD (1)
PMID 32269142, PMID 10850352, PMID 12843799, PMID 15940636, PMID 15994231, PMID 16912304, PMID 17030856, PMID 17563739, PMID 17889355, PMID 19264351, PMID 2106474, PMID 22755276, PMID 23071222, PMID 23190183, PMID 2452123, PMID 24576196, PMID 24669841, PMID 28657784, PMID 3129521, PMID 32299817, PMID 33683065, PMID 35113934, PMID 35880940, PMID 37500647, PMID 38238788, PMID 39871554, PMID 41592843, PMID 42715345, PMID 8368765, PMID 8399072
P30CA015704 (2), 2004 (1), 2009 (1), 2023 (1), K12CA076930 (1), K23CA175167 (1), P01CA015396 (1), P01CA225517 (1), P30CA006973 (1), P30CA011198 (1), P30CA015083 (1), U01CA062461 (1), U01CA154967 (1), UL1TR001082 (1)